FY2029 Earnings Estimate for ENTA Issued By HC Wainwright

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities researchers at HC Wainwright issued their FY2029 EPS estimates for shares of Enanta Pharmaceuticals in a note issued to investors on Tuesday, December 24th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will earn ($6.62) per share for the year. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share.

Several other equities research analysts also recently commented on the company. Robert W. Baird reduced their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. JMP Securities reiterated a “market outperform” rating and set a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Enanta Pharmaceuticals Stock Down 4.2 %

Shares of NASDAQ ENTA opened at $6.10 on Wednesday. The firm has a market cap of $129.28 million, a P/E ratio of -1.11 and a beta of 0.49. The company has a 50 day moving average of $9.52 and a 200 day moving average of $11.61. Enanta Pharmaceuticals has a twelve month low of $5.70 and a twelve month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The company had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company’s revenue was down 22.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.33) earnings per share.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC increased its stake in Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 20,478 shares during the period. Geode Capital Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after acquiring an additional 14,575 shares in the last quarter. Krensavage Asset Management LLC raised its position in shares of Enanta Pharmaceuticals by 19.7% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after purchasing an additional 246,736 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter worth approximately $360,000. Finally, State Street Corp grew its position in Enanta Pharmaceuticals by 6.4% during the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after purchasing an additional 27,147 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Insiders Place Their Bets

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 13.64% of the stock is currently owned by corporate insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.